logo

XNCR

XencorยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

XNCR Profile

Xencor, Inc.

A biotech company that develops monoclonal antibodies for cancer and autoimmune diseases

Biological Technology
--
12/03/2013
NASDAQ Stock Exchange
250
12-31
Common stock
465 North Halstead Street, Suite 200, Pasadena, CA 91107
--
Xencor, Inc., was founded in California in August 1997 and reorganized in Delaware in September 2004. The Company is a clinical-stage biopharmaceutical company focused on the discovery and development of engineered monoclonal antibodies and cytokine therapies for the treatment of cancer and autoimmune disease patients with unmet medical needs. The company utilizes protein engineering capabilities to increase understanding of protein structures and interactions and to design new technologies and XmAb drug candidates with improved properties.